* Alogliptin (Nesina) is the newest dipeptidyl peptidase-4 inhibitor approved for the treatment of type 2 diabetes. It's also available as part of two combination therapies—called Kazano when combined with metformin and Oseni when combined with pioglitazone.
* The most common adverse effects are upper respiratory infections, nasopharyngitis, and headache. Alogliptin may also cause acute pancreatitis, severe liver disease, and severe allergic reactions. Hypoglycemia is possible if the drug is administered with a sulfonylurea or with insulin.